Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Besifloxacin Hydrochloride

FDA-approved product (suspension/drops, ophthalmic), marketed as Besivance.

Registered studies
6
Lab records
2
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Besifloxacin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Eye infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
FDA pharmacologic class
Quinolone Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC S01AE08; FDA class Quinolone Antimicrobial

Repurposing investigation

Besifloxacin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae97.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis89.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

  • K. pneumoniae: measured active in 2 of 2 lab records
Open Besifloxacin Hydrochloride in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Besifloxacin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

    NCT01928693 · start 2013-07

    Registered record
    Registry ID
    NCT01928693
    Conditions
    Corneal Ulcers
    Interventions
    Besivance 0.6% Ophthalmic Suspension; Zymaxid 0.5% Ophthalmic Solution; Vigamox 0.5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-07
    Completion
    2014-05
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcers
    InterventionBesivance 0.6% Ophthalmic Suspension; Zymaxid 0.5% Ophthalmic Solution; Vigamox 0.5% Ophthalmic Solution
    PhasePhase 2
    Registry statusTerminated

  • Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

    NCT01330355 · start 2011-05

    Registered record
    Registry ID
    NCT01330355
    Conditions
    Bacterial Conjunctivitis
    Interventions
    Besivance; Gatifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2013-10
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Conjunctivitis
    InterventionBesivance; Gatifloxacin
    PhasePhase 3
    Registry statusTerminated

  • 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

    NCT01455233 · start 2010-09

    Registered record
    Registry ID
    NCT01455233
    Conditions
    Corneal Health; Cataract Surgery
    Interventions
    besivance; vigamox
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-09
    Completion
    2011-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Health; Cataract Surgery
    Interventionbesivance; vigamox
    PhasePhase 4
    Registry statusCompleted

  • Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

    NCT00824070 · start 2009-02

    Registered record
    Registry ID
    NCT00824070
    Conditions
    Cataract Extraction
    Interventions
    Besifloxacin hydrochloride; moxifloxacin hydrochloride; gatifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2009-08
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract Extraction
    InterventionBesifloxacin hydrochloride; moxifloxacin hydrochloride; gatifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Systemic Pharmacokinetics of BOL-303224-A

    NCT00407589 · start 2006-10

    Registered record
    Registry ID
    NCT00407589
    Conditions
    Conjunctivitis, Bacterial
    Interventions
    BOL-303224-A
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-10
    Completion
    2007-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctivitis, Bacterial
    InterventionBOL-303224-A
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

    NCT00348348 · start 2006-06

    Registered record
    Registry ID
    NCT00348348
    Conditions
    Acute Bacterial Conjunctivitis
    Interventions
    Besifloxacin; Moxifloxacin solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2007-07
    Enrolment
    1,161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Conjunctivitis
    InterventionBesifloxacin; Moxifloxacin solution
    PhasePhase 3
    Registry statusCompleted